The study selection was done based on the predetermined patient, intervention, control, and outcome (PICO) criteria, in which we used T2DM as the targeted patient, IDegAsp as intervention, other insulin therapy as the control (insulin glargine, insulin aspart, etc.), and primary outcomes of insulin use, that is the changes in hemoglobin A1C (HbA1C) value (for efficacy) and hypoglycemia incident rate (for safety). Here, INS is linked to type 2 diabetes mellitus.